Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PEPG | US
0.16
3.39%
Healthcare
Biotechnology
30/06/2024
25/03/2026
4.88
4.77
5.10
4.77
PepGen Inc. a clinical-stage biotechnology company focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51 an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1 an EDO peptide-conjugated PMO which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1 as well as EDO therapeutic candidates such as PGN-EDO53 PGN-EDO45 and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
77.0%1 month
95.7%3 months
109.6%6 months
205.4%-
-
1.88
0.13
0.10
-3.11
-
-
-94.36M
159.04M
159.04M
-
-
-
-
-58.97
7.73
5.64
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.88
Range1M
2.55
Range3M
3.60
Rel. volume
0.96
Price X volume
3.26M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | FENC | Biotechnology | 6.17 | 173.86M | 2.49% | 64.86 | -2193.44% |
| OBIO | OBIO | Biotechnology | 4.57 | 172.86M | -1.93% | n/a | 3.29% |
| Bolt Technology Corp | BOLT | Biotechnology | 4.5 | 172.19M | 4.90% | n/a | 22.00% |
| Ovid Therapeutics Inc | OVID | Biotechnology | 2.4 | 170.33M | -0.83% | n/a | 18.40% |
| Caribou Biosciences Inc. | CRBU | Biotechnology | 1.88 | 169.88M | 3.30% | n/a | 8.80% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 4.99 | 160.10M | 3.74% | n/a | -186.13% |
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 2.16 | 158.85M | 4.35% | n/a | 91.50% |
| Acumen Pharmaceuticals Inc. Common Stock | ABOS | Biotechnology | 2.63 | 158.01M | 1.54% | n/a | 11.57% |
| Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 5.32 | 157.76M | 1.72% | n/a | 6.50% |
| Vaxart Inc | VXRT | Biotechnology | 0.6782 | 154.25M | -0.26% | n/a | 28.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 14 | 156.21M | -0.92% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.35 | 150.13M | 1.08% | n/a | 286.96% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.1 | 99.37M | 0.66% | 9.09 | 39.79% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.04 | 97.76M | -0.41% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 12.05 | 75.45M | 0.75% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 2.4499 | 44.25M | 13.94% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.44 | 21.04M | -6.49% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.559 | 10.80M | 3.33% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.7001 | 5.64M | 6.94% | n/a | 204.46% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3644 | 3.47M | 5.62% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 109.64 | 72.80 | Riskier |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 159.04M | 3.66B | Emerging |